CDC Deputy Director Jennifer Shuford to Resign After Six Months

Dr Jennifer Shuford, who serves as the deputy director and chief medical officer at the Centers for Disease Control and Prevention (CDC), is preparing to exit her role following a tenure of just six months. According to an internal agency email obtained by the Guardian, Shuford’s departure is scheduled for 12 November, which falls immediately after the upcoming midterm elections. In a statement distributed via email by CDC Director Dr Erica Schwartz, Shuford cited personal reasons for her exit, stating that she is leaving to spend more time with her family. She expressed gratitude to President Donald Trump and Health Secretary Robert F Kennedy Jr for the opportunity to lead the agency, describing the experience as amazing.

Shuford’s appointment in April was part of a broader effort to stabilize the CDC’s senior leadership. She was selected as one of four new senior leaders tasked with restoring stability to the agency. This leadership overhaul followed the abrupt departure of the previous CDC director, Susan Monarez, who left her post less than a month after taking office. Monarez had publicly criticized the directives of Health Secretary Kennedy, describing them as unscientific. The new leadership team was intended to address the turmoil that had emerged within the agency during the early months of the administration.

Background

The appointment of Shuford and her colleagues was viewed positively by some public health organizations. The Association of State and Territorial Health Officials (ASTHO) welcomed the new leadership, noting that many in the sector were familiar with Shuford’s previous work as the Texas health commissioner. President Trump commended the collective on social media, characterizing them as esteemed physicians who held the requisite expertise, background, and advanced credentials to re-establish scientific excellence at the CDC.

However, the tenure of the new leadership team has coincided with significant policy changes under Health Secretary Kennedy. During the six months Shuford has served, Kennedy has implemented measures that critics argue undermine vaccine trust and access. Notably, the health secretary dismissed all 17 members of the CDC’s expert vaccine advisory panel. These actions have marked a distinct shift in the agency’s approach to public health guidance and scientific advisory processes. The rapid turnover in senior positions, including the brief tenure of Monarez and now the resignation of Shuford, highlights the ongoing instability within the CDC’s executive ranks.

Why it matters

The resignation of a senior scientific leader like Shuford carries implications for the continuity of public health operations at the CDC. As the chief medical officer, her role involved overseeing critical medical guidance and scientific integrity within the agency. Her departure, combined with the previous exit of Director Monarez, contributes to a pattern of high-level turnover that may affect the agency’s ability to maintain consistent policies and public trust. Public health leaders who initially supported the new leadership team may now reassess the agency’s direction in light of these personnel changes. The timing of her resignation, just after the midterm elections, suggests a strategic exit point for the administration’s early leadership experiments at the CDC.

What happens next

Shuford is expected to formally leave her post on 12 November. The CDC has not yet announced a successor for the deputy director and chief medical officer roles. The agency will likely need to initiate a search process to fill these vacancies, a procedure that may take several months. In the interim, the remaining members of the senior leadership team, including Director Dr Erica Schwartz, will continue to manage the agency’s operations. The departure adds to the list of unresolved leadership questions at the CDC, which has faced significant scrutiny over its recent policy shifts and staffing changes.